3-去(烯丙硫基)甲基-3-溴甲基阿尔噻嗪 | 7181-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 中文名称: 3-去(烯丙硫基)甲基-3-溴甲基阿尔噻嗪
• 英文名称: 6-Chlor-7-sulfamoyl-3-brommethyl-1,1-dioxy-3,4-dihydro-2H-1,2,4-benzothiadiazin
• 英文别名: 3-Brommethyl-6-chlor-1,1-dioxy-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazin；3-Brommethyl-6-chlor-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxid；6-Chlor-7-sulfamoyl-3-brommethyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxid；3-bromomethyl-6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,2,4]thiadiazine-7-sulfonic acid amide；2H-1,2,4-benzothiadiazine-7-sulfonamide-3-(bromomethyl)-6-chloro-3,4-dihydro-1,1-dioxide；3-bromomethyl-6-chloro-3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide；3-Des(allylthio)methyl-3-bromomethyl Althiazide；3-(bromomethyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
• CAS: 7181-60-4
• 化学式: C₈H₉BrClN₃O₄S₂
• 分子量: 390.666
• InChiKey: CVTBWXDLAWVRNO-UHFFFAOYSA-N

物化性质

• 熔点：
  218-220 °C
• 沸点：
  626.2±65.0 °C(Predicted)
• 密度：
  1.859±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-去(烯丙硫基)甲基-3-溴甲基阿尔噻嗪 在 potassium iodide 作用下， 以 丙酮 为溶剂， 生成 6-Chlor-3-jodmethyl-1,1-dioxy-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazin
  参考文献：
  名称：

  CRAVERI; ZONI, Bollettino Chimico Farmaceutico, 1961, vol. 100, p. 956 - 971

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氯-2,4-二磺酰胺基苯胺 、 2-溴-1,1-二乙氧基乙烷 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 3-去(烯丙硫基)甲基-3-溴甲基阿尔噻嗪
  参考文献：
  名称：

  3-Substituted Dihydrobenzothiadiazine 1,1-Dioxides as Diuretic Agents¹

  摘要：

  DOI：

  10.1021/jo01068a053

文献信息

• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。
• NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：GARVEY David S.

  公开号：US20080255101A1

  公开（公告）日：2008-10-16

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  这项发明描述了新颖的组合物和试剂盒，包括至少一种增强一氧化氮利尿化合物或其药学上可接受的盐，并且可选地，还包括至少一种增强一氧化氮化合物和/或至少一种治疗剂。该发明还提供了以下方法：(a)治疗由过度水和/或电解质潴留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗先兆子痫；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)治疗高脂血症。增强一氧化氮利尿化合物包括至少一个增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点连接到利尿化合物上，通过无法水解的键或基团连接。
• Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0088350A1

  公开（公告）日：1983-09-14

  The compounds of the present invention are compounds of the formula and the pharmaceutically acceptable esters and salts thereof wherein R' and R2 independently are hydrogen or lower alkyl; the group is one of the structures II to VIII specified in the description, one of R3, R4 and R5 is a group Z-(CH2)0-6-' wherein Z is selected from Z' to Z10 being as defined in the description and the other of the groups R3, R4 and R5 are as also defined. The compounds are useful as antihypertensive agents, in the treatment of congestive heart failure and glaucoma. Their preparation and pharmaceutical compositions are disclosed.

  本发明的化合物是如下式的化合物 及其药学上可接受的酯和盐 其中 R' 和 R2 分别为氢或低级烷基；基团 是描述中规定的结构 II 至 VIII 之一，R3、R4 和 R5 中的一个是基团 Z-(CH2)0-6-'，其中 Z 选自描述中定义的 Z' 至 Z10，基团 R3、R4 和 R5 中的另一个也如定义。这些化合物可用作降压药、治疗充血性心力衰竭和青光眼。已公开了它们的制备方法和药物组合物。
• CRAVERI; ZONI, Bollettino Chimico Farmaceutico, 1961, vol. 100, p. 956 - 971
  作者：CRAVERI、ZONI

  DOI：——

  日期：——
• 3-Substituted Dihydrobenzothiadiazine 1,1-Dioxides as Diuretic Agents¹
  作者：JOHN G. TOPLISS、MARGARET H. SHERLOCK、FRANK H. CLARKE、MARIA C. DALY、BERIT W. PETTERSEN、JANET LIPSKI、NATHAN SPERBER

  DOI：10.1021/jo01068a053

  日期：1961.10